Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marwa S Hamza, Samia A Shouman, Raafat Abdelfattah, Heba S Moussa & Mervat M Omran. (2022) Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients. Drug Design, Development and Therapy 16, pages 1595-1604.
Read now
Read now
Articles from other publishers (15)
Mohammed G. Maslub, Mahasen A. Radwan, Nur Aizati Athirah Daud & Abubakar Sha’aban. (2023) Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. European Journal of Medical Research 28:1.
Crossref
Crossref
Meike Kaehler & Ingolf Cascorbi. 2023.
Fatemeh Mohammadi, Golale Rostami, Dlnya Assad, Mohammad Shafiei, Mohammad Hamid & Hasan Jalaeikhoo. (2021)
Association of
SLC22A1
,
SLCO1B3
Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia
. Laboratory Medicine 52:6, pages 584-596.
Crossref
Crossref
Meike Kaehler & Ingolf Cascorbi. (2021) Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. Frontiers in Pharmacology 12.
Crossref
Crossref
Mervat M. Omran, Raafat Abdelfattah, Heba S. Moussa, Nelly Alieldin & Samia A. Shouman. (2020) Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients. Frontiers in Oncology 10.
Crossref
Crossref
Fouzia Radouani, Lyndon Zass, Yosr Hamdi, Jorge da Rocha, Reem Sallam, Sonia Abdelhak, Samah Ahmed, Maryame Azzouzi, Ichrak Benamri, Alia Benkahla, Balkiss Bouhaouala-Zahar, Melek Chaouch, Haifa Jmel, Rym Kefi, Ayoub Ksouri, Judit Kumuthini, Phumlani Masilela, Collen Masimirembwa, Houcemeddine Othman, Sumir Panji, Lilia Romdhane, Chaimae Samtal, Rania Sibira, Kais Ghedira, Faisal Fadlelmola, Samar Kamal Kassim & Nicola Mulder. (2020) A review of clinical pharmacogenetics Studies in African populations. Personalized Medicine 17:2, pages 155-170.
Crossref
Crossref
Ravindran Ankathil, Husin Azlan, Abu Abdullah Dzarr & Abdul Aziz Baba. (2018) Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics 19:5, pages 475-393.
Crossref
Crossref
Najlaa Maddin, Azlan Husin, Siew Hua Gan, Baba Abdul Aziz & Ravindran Ankathil. (2016) Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia. Oncology and Therapy 4:2, pages 303-314.
Crossref
Crossref
Sylvia Chen, Natalia Sutiman & Balram Chowbay. (2016) Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients. Pharmacogenomics 17:17, pages 1941-1955.
Crossref
Crossref
Claudia Neul, Elke Schaeffeler, Alex Sparreboom, Stefan Laufer, Matthias Schwab & Anne T. Nies. (2016) Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends in Pharmacological Sciences 37:11, pages 904-932.
Crossref
Crossref
B. A. Adeagbo, O. O. Bolaji, T. A. Olugbade, M. A. Durosinmi, R. A. Bolarinwa & C. Masimirembwa. (2016) Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. Journal of Clinical Pharmacy and Therapeutics 41:5, pages 546-551.
Crossref
Crossref
Shantashri Vaidya, Kanjaksha Ghosh, Chandrakala Shanmukhaiah & Babu Rao Vundinti. (2015) Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. European Journal of Pharmacology 765, pages 124-130.
Crossref
Crossref
Ningning Dong, Fandong Meng, Yongdong Wu, Mingyu Wang, Yongchun Cui & Shutian Zhang. (2015) Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. Tumor Biology 36:10, pages 7691-7698.
Crossref
Crossref
Feng Jiang, Lei Chen, Ying-Cheng Yang, Xian-ming Wang, Ruo-Yu Wang, Liang Li, Wen Wen, Yan-Xin Chang, Cai-Yang Chen, Jing Tang, Gao-Mi-Yang Liu, Wen-Tao Huang, Lin Xu & Hong-Yang Wang. (2015) CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling. Cancer Research 75:7, pages 1470-1481.
Crossref
Crossref
Jason A. Sprowl & Alex Sparreboom. (2014) Uptake Carriers and Oncology Drug Safety. Drug Metabolism and Disposition 42:4, pages 611-622.
Crossref
Crossref